Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Cash from Financing Activities (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Cash from Financing Activities for 11 consecutive years, with -$6.9 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities fell 367.36% year-over-year to -$6.9 million; the TTM value through Mar 2026 reached $317.3 million, up 21537.22%, while the annual FY2025 figure was $323.0 million, 5983301.26% up from the prior year.
  • Cash from Financing Activities hit -$6.9 million in Q1 2026 for Crescent Biopharma, down from $178.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $178.9 million in Q4 2025 and bottomed at -$6.9 million in Q1 2026.
  • Average Cash from Financing Activities over 4 years is $38.5 million, with a median of $20114.0 recorded in 2023.
  • Year-over-year, Cash from Financing Activities plummeted 99.98% in 2024 and then plummeted 30438.91% in 2025.
  • Crescent Biopharma's Cash from Financing Activities stood at $999.0 in 2023, then soared by 390.29% to $4898.0 in 2024, then surged by 3651594.57% to $178.9 million in 2025, then plummeted by 103.88% to -$6.9 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$6.9 million, $178.9 million, and $146.9 million for Q1 2026, Q4 2025, and Q2 2025 respectively.